Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues

Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, ​reinforcing the biotech pipeline for the fall IPO window.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。